NBP607-Y

SK Chemicals Co., Ltd. · Phase 3 active Biologic

NBP607-Y is a dual-acting agent that modulates immune function and promotes tissue regeneration through a novel mechanism.

NBP607-Y is a dual-acting agent that modulates immune function and promotes tissue regeneration through a novel mechanism. Used for Tissue regeneration and repair (specific indication under investigation in Phase 3).

At a glance

Generic name	NBP607-Y
Sponsor	SK Chemicals Co., Ltd.
Modality	Biologic
Therapeutic area	Regenerative Medicine
Phase	Phase 3

Mechanism of action

While specific mechanistic details remain proprietary, NBP607-Y is being developed as a regenerative medicine therapeutic. The drug is designed to address tissue damage and promote healing through immunomodulatory pathways. Phase 3 development suggests clinical efficacy has been demonstrated in earlier trials.

Approved indications

Tissue regeneration and repair (specific indication under investigation in Phase 3)

Common side effects

No common side effects on file.

Key clinical trials

Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NBP607-Y CI brief — competitive landscape report
NBP607-Y updates RSS · CI watch RSS
SK Chemicals Co., Ltd. portfolio CI